ES2916450T3 - Método para la detección de discrasia de células plasmáticas - Google Patents

Método para la detección de discrasia de células plasmáticas Download PDF

Info

Publication number
ES2916450T3
ES2916450T3 ES18755985T ES18755985T ES2916450T3 ES 2916450 T3 ES2916450 T3 ES 2916450T3 ES 18755985 T ES18755985 T ES 18755985T ES 18755985 T ES18755985 T ES 18755985T ES 2916450 T3 ES2916450 T3 ES 2916450T3
Authority
ES
Spain
Prior art keywords
splice variants
expression level
subject
biomarkers
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18755985T
Other languages
English (en)
Spanish (es)
Inventor
Irvin Mark Modlin
Mark Kidd
Ignat Drozdov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Application granted granted Critical
Publication of ES2916450T3 publication Critical patent/ES2916450T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
ES18755985T 2017-07-21 2018-07-18 Método para la detección de discrasia de células plasmáticas Active ES2916450T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (1)

Publication Number Publication Date
ES2916450T3 true ES2916450T3 (es) 2022-07-01

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18755985T Active ES2916450T3 (es) 2017-07-21 2018-07-18 Método para la detección de discrasia de células plasmáticas

Country Status (13)

Country Link
US (3) US20190025311A1 (enExample)
EP (1) EP3655553B1 (enExample)
JP (1) JP7223741B2 (enExample)
KR (1) KR102785072B1 (enExample)
CN (1) CN111194356B (enExample)
AU (1) AU2018304242B2 (enExample)
BR (1) BR112020000791A2 (enExample)
DK (1) DK3655553T3 (enExample)
ES (1) ES2916450T3 (enExample)
IL (1) IL271465B2 (enExample)
MX (1) MX2020000785A (enExample)
PL (1) PL3655553T3 (enExample)
WO (1) WO2019018540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000791A2 (pt) 2017-07-21 2020-07-21 Liquid Biopsy Research LLC métodos para detecção de discrasia de célula plasmática
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
AU2021281287A1 (en) * 2020-05-29 2023-01-19 Bio-Techne Corporation Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
JP2004313167A (ja) 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
EP1766086A4 (en) * 2004-05-21 2009-10-28 Univ Arkansas USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
CN102361991A (zh) * 2009-01-02 2012-02-22 阿肯色大学托管委员会 硼替佐米在预测多发性骨髓瘤患者生存率中的应用
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma
BR112020000791A2 (pt) 2017-07-21 2020-07-21 Liquid Biopsy Research LLC métodos para detecção de discrasia de célula plasmática

Also Published As

Publication number Publication date
DK3655553T3 (da) 2022-06-20
US20260118360A1 (en) 2026-04-30
CN111194356A (zh) 2020-05-22
IL271465A (en) 2020-01-30
AU2018304242B2 (en) 2023-04-27
BR112020000791A2 (pt) 2020-07-21
JP2020528274A (ja) 2020-09-24
AU2018304242A1 (en) 2020-01-16
WO2019018540A1 (en) 2019-01-24
IL271465B2 (en) 2023-08-01
KR20200029528A (ko) 2020-03-18
MX2020000785A (es) 2020-11-06
US20230022417A1 (en) 2023-01-26
EP3655553B1 (en) 2022-03-23
PL3655553T3 (pl) 2022-09-26
US12366575B2 (en) 2025-07-22
KR102785072B1 (ko) 2025-03-20
IL271465B1 (en) 2023-04-01
CA3067730A1 (en) 2019-01-24
US20190025311A1 (en) 2019-01-24
CN111194356B (zh) 2024-04-23
JP7223741B2 (ja) 2023-02-16
EP3655553A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
Jiang et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment
Na et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death
Wozniak et al. Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
JP6203209B2 (ja) 早期結腸直腸癌の検出のための血漿マイクロｒｎａ
JP6704861B2 (ja) 癌処置のための個別化三剤治療を選択するための方法
WO2013138237A9 (en) Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
AU2017341084A1 (en) Classification and prognosis of cancer
Renieri et al. Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients
US11993816B2 (en) Circulating microRNA as biomarkers for endometriosis
Zuo et al. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes
US20180230545A1 (en) Method for the prediction of progression of bladder cancer
US10036070B2 (en) Methods and means for molecular classification of colorectal cancers
US20210238696A1 (en) Biomarkers for the Identification of Prostate Cancer and Methods of Use
Pozzo et al. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
EP3655553B1 (en) Methods for detection of plasma cell dyscrasia
US20150159225A1 (en) Uveal melanoma prognosis
ES2920288T3 (es) Procedimientos para la detección de melanoma
CN112063714A (zh) 一种与结直肠癌相关的miRNA及其应用
US20160304961A1 (en) Method for predicting the response to chemotherapy treatment in patients suffering from colorectal cancer
De Viron et al. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia
Eslami et al. High expression of long noncoding RNA NORAD is associated with poor clinical outcomes in non-M3 acute myeloid leukemia patients
ES2481819B1 (es) Método de evaluación para evaluar una posibilidad de cáncer de mama
HK40030202A (en) Methods for detection of plasma cell dyscrasia
HK40030202B (en) Methods for detection of plasma cell dyscrasia